A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

The outcome of patients with refractory leukemia and myelodysplasia is poor, and new therapies are needed. The antiapoptotic proteins of the Bcl-2 family are overexpressed in these malignancies and are potential therapeutic targets. Therefore, we conducted a phase I clinical trial of the small-molec...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Aaron D. Schimmer, Susan O’Brien, Hagop M. Kantarjian, Joseph Brandwein, Bruce D. Cheson, Mark D. Minden, Karen Yee, Farhad Ravandi, Francis J. Giles, Andre C. Schuh, Vikas Gupta, Michael Andreeff, Charles Koller, Hong Chang, Suzanne Kamel‐Reid, Mark S. Berger, Jean Viallet, Gautam Borthakur
Natura: Artigo
Lingua:inglese
Pubblicazione: 2008
Accesso online:https://doi.org/10.1158/1078-0432.ccr-08-0999
https://clincancerres.aacrjournals.org/content/clincanres/14/24/8295.full.pdf
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Accesso online

https://doi.org/10.1158/1078-0432.ccr-08-0999
https://clincancerres.aacrjournals.org/content/clincanres/14/24/8295.full.pdf

Documenti analoghi